Clinical trials: Oesophageal Cancer Nos
Liver Cancer, Pancreas Cancer
PRIORITY-CONNECT 2 Pilot Trial
The provision of preoperative interventions (prehabilitation: including exercise, nutrition, and psychological treatment) have been reported to reduce postoperative complications by as much as 50% and reduce hospital stay by up…
- Conditions
- Liver Cancer, Pancreas Cancer, Oesophageal Cancer, Gastric Cancer
- Trial name
- NCT06212700
- Testing
- Preoperative Exercise, Postoperative Exercise, Preoperative Nutrition
- Where
- 2 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Surgical Outcomes Research Centre (SOuRCe)
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy
This study prospectively recruited esophageal squamous-cell carcinoma patients who received nasogastric tube (NG), gastrostomy feeding and oral intake to compare the changes in nutritional status and quality of life during…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Enteral Nutrition
- Trial name
- NCT04199832
- Testing
- Dietary guidance
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Malnutrition, Esophageal Cancer
INEC Study: Immuno-modulating Enteral Nutrition in Cancer
The aim of this study is to investigate if enteral immunonutrition of head and neck or esophageal cancer patients, using an arginine, omega 3 fatty acid, nucleotides-enhanced diet [Impact (R), Novartis] versus a standard enteral…
- Conditions
- Malnutrition, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00333099
- Testing
- Impact (R) Enteral Nutrition, impact
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Clermont-Ferrand
Colorectal Cancer, Pancreatic Cancer
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT02584244
- Testing
- LUM015, LUM 2.6 Imaging Device
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lumicell, Inc.
Esophageal Cancer, Lymph Node Metastases
99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma
The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China, which become a severe challenge for public health.
- Conditions
- Esophageal Cancer, Lymph Node Metastases, Diagnoses Disease
- Trial name
- NCT04504565
- Testing
- 99mTc-3PRGD2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Esophagus Cancer
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
- Trial name
- NCT05023928
- Testing
- Tumor antigen-sensitized DC vaccine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sichuan University
Head and Neck Cancer, Hearing Loss
Maximizing Quality of Life After Cancer Through Rehabilitation
Treatment for head and neck cancer (HNC) often includes cisplatin chemotherapy and radiation. This treatment causes hearing loss and trouble swallowing in 70% of patients.
- Conditions
- Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
- Trial name
- TIMELY REHAB (NCT07622407)
- Testing
- TIMELY REHAB
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- VA Office of Research and Development
Gastric Cancer (GC), Premalignant Lesion
AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development.
- Conditions
- Gastric Cancer (GC), Premalignant Lesion, Gastric Intestinal Metaplasia, Atrophic Gastritis
- Trial name
- NCT07605312
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer, Amino Acid Transport Disorder
Research on the Role of SLC1A5 in the Development of Esophageal Cancer
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.
- Trial name
- NCT02633436
- Testing
- SLC1A5 expression
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Tumor Regression Grade
PPIO-009 Tumor Regression Grade and Tumor Location in Esophageal Cancer
At present, the evaluation of the effect of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal cancer is mainly based on postoperative pathology, among which, the pathological assessment of…
- Trial name
- NCT06453395
- Testing
- Patients were grouped according to tumor location
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Oesophageal Cancer, Gastric Cancer
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
The overall aim of this study is to assess the feasibility of a mHealth prehabilitation programme delivered via a mobile app for people with oesophago-gastric cancer by evaluating its user satisfaction and acceptance.
- Conditions
- Oesophageal Cancer, Gastric Cancer, Prehabilitation, mHealth Application
- Trial name
- NCT06046846
- Testing
- Asensei app
- Volunteers
- 20 people
- Sponsor
- Queen Margaret University
Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable…
- Trial name
- REVO (NCT05007145)
- Testing
- PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 92 people
- Sponsor
- Fujian Cancer Hospital
Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme
- Trial name
- NCT05977322
- Testing
- 68Ga-FF58, 177Lu-FF58
- Where
- 5 sites in Israel, Netherlands and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Esophagus Cancer
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC.
- Trial name
- RICE-Chronos (NCT05615129)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Guangdong Provincial People's Hospital
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Cancer
Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
More than 50% of patients with esophageal cancer have locally advanced or metastatic disease at presentation. The use of chemotherapy for this patient group is increasing with the intention of local and distant tumor control…
- Trial name
- POWER (NCT01627379)
- Testing
- Cisplatin, 5-FU, Panitumumab
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- AIO-Studien-gGmbH
Esophagus Cancer
TTS Esophageal HILZO Stent: A Safety and Feasibility Study
A multicenter non-randomized prospective clinical study assessing the safety and feasibility of the esophageal through-the-scope HILZO Covered self-expandable metal stent placement for palliation of malignant dysphagia
- Trial name
- HILZO (NCT03269903)
- Testing
- HILZO esophageal stent
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.